BRPI0509271A - formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23) - Google Patents

formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)

Info

Publication number
BRPI0509271A
BRPI0509271A BRPI0509271-0A BRPI0509271A BRPI0509271A BR PI0509271 A BRPI0509271 A BR PI0509271A BR PI0509271 A BRPI0509271 A BR PI0509271A BR PI0509271 A BRPI0509271 A BR PI0509271A
Authority
BR
Brazil
Prior art keywords
dosage forms
pharmaceutical dosage
alanyl
acetyl
phthalimideethoxy
Prior art date
Application number
BRPI0509271-0A
Other languages
English (en)
Inventor
Marija Bogataj
Ales Mrhar
Anton Lavric
Manica Cerne
Doris Tibaut
Anton Stalc
Uros Urleb
Tatjana Mateovic
Greta Cof
Janez Kerk
Rok Dreu
Fumio Yoneda
Shizuko Muraoka
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of BRPI0509271A publication Critical patent/BRPI0509271A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMAS DE DOSAGENS FARMACêUTICAS GASTRORRESISTENTES COMPREENDENDO áCIDO N-(2-(2-FTALIMIDAE-TóXI)-ACETIL-L-ALANIL-D-GLUTãMICO (LK-423)". A presente invenção refere-se às formas de dosagens farmacêuticas que permite uma liberação alvejada e/ou controlada de uma substância ativa para as regiões selecionadas do trato gastrointestinal de humanos ou animais. As formas de dosagens farmacêuticas preferivelmente compreendem a substância ativa ácido N-(2-(2-ftalimidoetóxi)-acetil)-L-alanil-D-glutâmico (designado como LK 423). Os métodos de tratamento de doenças inflamatórias crónicas do trato gastrointestinal de humanos e/ou animais empregando-se as formas de dosagens farmacêuticas da invenção são descritos.
BRPI0509271-0A 2004-03-26 2005-03-24 formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23) BRPI0509271A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200400094 2004-03-26
PCT/EP2005/003175 WO2005092295A1 (en) 2004-03-26 2005-03-24 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)

Publications (1)

Publication Number Publication Date
BRPI0509271A true BRPI0509271A (pt) 2007-09-04

Family

ID=34964906

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509271-0A BRPI0509271A (pt) 2004-03-26 2005-03-24 formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)

Country Status (15)

Country Link
US (1) US20100183714A1 (pt)
EP (1) EP1734933B1 (pt)
JP (1) JP2007530492A (pt)
CN (1) CN1956707B (pt)
AR (1) AR048342A1 (pt)
AT (1) ATE468846T1 (pt)
AU (1) AU2005226927B2 (pt)
BR (1) BRPI0509271A (pt)
CA (1) CA2559685A1 (pt)
DE (1) DE602005021475D1 (pt)
MY (1) MY145329A (pt)
PE (1) PE20051163A1 (pt)
RU (1) RU2375047C2 (pt)
TW (1) TW200600121A (pt)
WO (1) WO2005092295A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
CA2678131A1 (en) * 2006-11-17 2008-05-22 Antoine Andremont Colonic delivery using zn/pectin beads with a eudragit coating.
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
RS56049B1 (sr) 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
CN107921073B (zh) * 2015-06-01 2022-10-18 塞诺生物科学股份有限公司 用于调节肠道微生物群及管理体重的方法和组合物
BR112018077032A2 (pt) * 2016-06-23 2019-04-02 Nutrivert Llc método para aprimorar o crescimento ou a conversão alimentar em um animal, uso de pgn, mdp ou um análogo de mdp na preparação de um medicamento e pgn, mdp ou um análogo de mdp
CA3043124A1 (en) * 2016-11-09 2018-05-17 Engene, Inc. Intestinal expression of programmed death ligand 1
US11033490B2 (en) 2016-12-14 2021-06-15 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
BR112019011689A2 (pt) * 2016-12-14 2019-10-22 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de tnf
TW201834710A (zh) * 2016-12-14 2018-10-01 美商寶珍那提公司 以整合素抑制劑治療胃腸道疾病
CN108968074B (zh) * 2018-06-06 2021-09-28 福建省农业科学院农业工程技术研究所 一种结肠靶向递送的银耳糖醛酸多糖-芙蓉李花青素复合物及其制备方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
SI9011830B (sl) * 1990-09-27 1999-12-31 Univerza V Ljubljani, Fakulteta Za Farmacijo Novi N-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, ki jih vsebujejo
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems

Also Published As

Publication number Publication date
EP1734933B1 (en) 2010-05-26
US20100183714A1 (en) 2010-07-22
AR048342A1 (es) 2006-04-19
RU2375047C2 (ru) 2009-12-10
RU2006137660A (ru) 2008-05-10
CN1956707B (zh) 2010-12-29
AU2005226927B2 (en) 2010-09-23
TW200600121A (en) 2006-01-01
CA2559685A1 (en) 2005-10-06
DE602005021475D1 (de) 2010-07-08
EP1734933A1 (en) 2006-12-27
MY145329A (en) 2012-01-31
ATE468846T1 (de) 2010-06-15
AU2005226927A1 (en) 2005-10-06
PE20051163A1 (es) 2006-02-21
WO2005092295A1 (en) 2005-10-06
CN1956707A (zh) 2007-05-02
JP2007530492A (ja) 2007-11-01

Similar Documents

Publication Publication Date Title
BRPI0509271A (pt) formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)
CY1119148T1 (el) Φαρμακευτικες συνθεσεις και συναφεις μεθοδοι χορηγησης
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
MA33989B1 (fr) Formulation d'anticorps et régimes thérapeutiques
CY2017014I1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
EA200971053A1 (ru) Способы лечения кожных язв
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
DE602007004093D1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
ATE466604T1 (de) Medizinische vorrichtung zur verabreichung therapeutischer wirkstoffe über unterschiedliche zeitabschnitte
EA201100814A1 (ru) Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик
EA200800782A1 (ru) ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
FR2902007B1 (fr) Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
Lopes et al. Region-specific alterations of AMPA receptor phosphorylation and signaling pathways in the pilocarpine model of epilepsy
BRPI0720500A8 (pt) Preparação líquida transdérmica
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
EA201300125A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний желудочно-кишечного тракта функциональной этиологии
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.